|
|
HOME >>
Pharmaceuticals API List 4 >>
Cefotetan Sodium
Cefotetan Sodium
CAS NO: 74356-00-6
Cefotetan disodium is a semisynthetic, beta-lactamase resistant,
cephalosporin (cephamycin) antibiotic.
In vitro studies indicate that the bactericidal action of cefotetan results
from an interference of bacterial cell wall synthesis by inhibiting the
cross-linking of peptidoglycan.
Dosage And Administration:
Treatment: Adults: The usual adult dosage is 1 or 2 g administered i.v. or
i.m. every 12 hours for 5 to 10 days.
Proper dosage and route of administration should be determined by the
condition of the patient, severity of the infection and susceptibility of
the causative organism. Therapy may be started while awaiting the results of
susceptibility testing.
The i.v. route is preferable for patients with bacteremia, bacterial
septicemia or other severe or life-threatening infections or for patients
who may be at risk particularly if shock is present or impending.
Availability And Storage: 1 g: Each vial of dry, white to pale yellow
powder contains: cefotetan disodium equivalent to 1 g cefotetan activity for
i.v. and i.m. administration. Nonmedicinal ingredients: sodium bicarbonate.
Sodium: 3.4 mmol (78.7 mg). Vials of 10 mL.
2 g: Each vial of dry, white to pale yellow powder contains: cefotetan
disodium equivalent to 2 g cefotetan activity for i.v. and i.m.
administration. Nonmedicinal ingredients: sodium bicarbonate. Sodium: 6.8
mmol (157.4 mg). Vials of 20 mL.
Store below 25°C and protect from light.
Drug Interactions:
Renal function should be carefully monitored, especially if high dosages of
the aminoglycosides are to be administered or if therapy is prolonged,
because of the potential nephrotoxicity and ototoxicity of aminoglycosidic
antibiotics.
Although, to date, this has not been noted when cefotetan was given alone,
increased nephrotoxicity has been reported following concomitant
administration of cephalosporins and aminoglycoside antibiotics.
However, at the recommended dose, enhancement of nephrotoxicity is unlikely
to be a problem with cefotetan.
|
©
2004 - 2019 Taj
Pharmaceuticals Limited .
All rights reserved
India
